Product Catalog [{"id":"463","name":"Evaluation of Parsaclisib plus Bendamustine and Rituximab in patients with Newly Diagnosed Mantle Cell Lymphoma","price":1,"sku":"lymphoma-trial-2","brand":false,"position":1,"category":"Medicines\/| Clinical Trials"},{"id":"462","name":"Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-3","brand":false,"position":2,"category":"Medicines\/| Clinical Trials"},{"id":"461","name":"Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-4","brand":false,"position":3,"category":"Medicines\/| Clinical Trials"},{"id":"460","name":"Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","price":1,"sku":"lymphoma-leukemia-trial-1","brand":false,"position":4,"category":"Medicines\/| Clinical Trials"},{"id":"459","name":"Evaluation of Parsaclisib plus Ruxolitinib in patients with Myelofibrosis who have not responded to Ruxolitinib alone","price":1,"sku":"myelofibrosis-trial-1","brand":false,"position":5,"category":"Medicines\/| Clinical Trials"},{"id":"458","name":"Evaluation of Nivolumab plus Docetaxel in men with Prostate Cancer","price":1,"sku":"prostate-cancer-trial-1","brand":false,"position":6,"category":"Medicines\/| Clinical Trials"}]
Call our support: +31 20 8084 414
Google Reviews
4.8
Toggle Nav
Search
Advanced Search
You are reading an automatically translated version of our website that may contain translation errors.
Change to English
Menu
Account

| Clinical Trials access options

  1. Evaluation of Nivolumab plus Docetaxel in men with Prostate Cancer
    Evaluation of Nivolumab plus Docetaxel in men with Prostate Cancer
    Prostate Cancer
    Price available on request
  2. Evaluation of Parsaclisib plus Ruxolitinib in patients with Myelofibrosis who have not responded to Ruxolitinib alone
    Evaluation of Parsaclisib plus Ruxolitinib in patients with Myelofibrosis who have not responded to Ruxolitinib alone
    Myelofibrosis
    Price available on request
  3. Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
    Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
    Leukemia or Lymphoma
    Price available on request
  4. Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment
    Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment
    Lymphoma
    Price available on request
  5. Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment
    Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment
    Lymphoma
    Price available on request
  6. Evaluation of Parsaclisib plus Bendamustine and Rituximab in patients with Newly Diagnosed Mantle Cell Lymphoma
    Evaluation of Parsaclisib plus Bendamustine and Rituximab in patients with Newly Diagnosed Mantle Cell Lymphoma
    Lymphoma
    Price available on request
View as Grid List

6 Items

Set Descending Direction
Explore disease areas
US United States 1